Story perspectives

Retatrutide Beats Ozempic in 80-Week Trial Results

By Drooid · Oct 28, 2026 · How we work

Read the story

Story summary

Summary

Eli Lilly announced retatrutide outperformed Ozempic in an 80-week Phase 3 trial.
Retatrutide reduced A1C by 2.2 percentage points, compared with 1.8 points for Ozempic.
Patients on 9 mg and 12 mg retatrutide lost 44.3 lb and 47.4 lb, while Ozempic users lost 20.9 lb.
Diarrhea occurred in 32.7 % (12 mg) and 28.3 % (9 mg) of retatrutide users versus 26.4 % for Ozempic.
Lilly will submit a Biologics License Application for retatrutide to the FDA in early 2027.

Summary

Eli Lilly’s retatrutide showed strong weight-loss results in an 80-week per-protocol analysis.
The head-to-head trial directly compared retatrutide with Novo Nordisk’s GLP-1 drug.
Payers are evaluating innovative payment models for costly obesity drugs such as retatrutide.
The win heightens competition in the expanding GLP-1/dual-agonist obesity market.
Companies must navigate recent FDA policy shifts affecting obesity-drug approvals.

1 of 2

Lilly Outperforms Ozempic

Eli Lilly announced retatrutide outperformed Ozempic in an 80-week Phase 3 trial.
Retatrutide reduced A1C by 2.2 percentage points, compared with 1.8 points for Ozempic.
Patients on 9 mg and 12 mg retatrutide lost 44.3 lb and 47.4 lb, while Ozempic users lost 20.9 lb.
Diarrhea occurred in 32.7 % (12 mg) and 28.3 % (9 mg) of retatrutide users versus 26.4 % for Ozempic.
Lilly will submit a Biologics License Application for retatrutide to the FDA in early 2027.

1 / 2